{rfName}

Documents and Files

License and Use

Licencia

Altmetrics

Analysis of institutional authors

Castrejon De Anta, NataliaAuthorRivas-Delgado, ACorresponding AuthorNadeu, FAuthorEnjuanes, AAuthorMozas, PAuthorMagnano, LAuthorRovira, JAuthorDlouhy, IAuthorMartin, SAuthorRodriguez, SAuthorPinyol, MAuthorBaumann, TAuthorBea, SAuthorBalague, OAuthorDelgado, JAuthorVillamor, NAuthorSetoain, XAuthorCampo, EAuthorGine, EAuthorLopez-Guillermo, AAuthor

Share

December 14, 2021
Publications
>
Article
No

Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study

Publicated to: CLINICAL CANCER RESEARCH. 27 (2): 513-521 - 2021-01-15 27(2), DOI: 10.1158/1078-0432.ccr-20-2558

Authors:

Rivas-Delgado, Alfredo; Nadeu, Ferran; Enjuanes, Anna; Casanueva-Eliceiry, Sebastian; Mozas, Pablo; Magnano, Laura; de Anta, Natalia Castrejon; Rovira, Jordina; Dlouhy, Ivan; Martin, Silvia; Osuna, Miguel; Rodriguez, Sonia; Simo, Marc; Pinyol, Magda; Baumann, Tycho; Bea, Silvia; Balague, Olga; Delgado, Julio; Villamor, Neus; Setoain, Xavier; Campo, Elias; Gine, Eva; Lopez-Guillermo, Armando
[+]

Affiliations

Centro de Investigacion Biomedica en Red de Bioingenieria - Author
Centros de Investigacion Biomedica en Red (CIBER) - Author
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain - Author
Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain - Author
Hosp Clin Barcelona, Dept Hematol, Villarroel 170, Barcelona 08036, Spain - Author
Hosp Clin Barcelona, Dept Nucl Med, Barcelona, Spain - Author
Hosp Clin Barcelona, Dept Pathol, Hematopathol Unit, Barcelona, Spain - Author
Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain - Author
Hospital Clinic Barcelona - Author
Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain - Author
Inst Univ Dexeus, Dept Nucl Med, Grp Ouiron Salud, Barcelona, Spain - Author
Institut d'Investigacions Biomèdiques August Pi i Sunyer - IDIBAPS - Author
Institut Universitari Dexeus - Author
Univ Barcelona, Barcelona, Spain - Author
Universitat de Barcelona - Author
‎ Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain - Author
‎ Ctr Invest Biomed Red Canc CIBERONC, Barcelona, Spain - Author
‎ Hosp Clin Barcelona, Dept Hematol, Villarroel 170, Barcelona 08036, Spain - Author
‎ Hosp Clin Barcelona, Dept Nucl Med, Barcelona, Spain - Author
‎ Hosp Clin Barcelona, Dept Pathol, Hematopathol Unit, Barcelona, Spain - Author
‎ Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain - Author
‎ Inst Invest Biomed August Pi i Sunyer IDIBAPS, Barcelona, Spain - Author
‎ Inst Univ Dexeus, Dept Nucl Med, Grp Ouiron Salud, Barcelona, Spain - Author
‎ Univ Barcelona, Barcelona, Spain - Author
See more

Abstract

Purpose: We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based cohort to determine the mutational profile, assess tumor burden, and estimate its impact in response rate and outcome in patients with diffuse large B-cell lymphoma (DLBCL). Experimental Design: A total of 100 patients were diagnosed with DLBCL during the study period. Mutational status of 112 genes was studied in cfDNA by targeted next-generation sequencing. Paired formalin-fixed, paraffin-embedded samples and volumetric PET/CT were assessed when available. Results: Appropriate cfDNA to perform the analyses was obtained in 79 of 100 cases. At least one mutation could be detected in 69 of 79 cases (87%). The sensitivity of cfDNA to detect the mutations was 68% (95% confidence interval, 56.2-78.7). The mutational landscape found in cfDNA samples was highly consistent with that shown in the tissue and allowed genetic classification in 43% of the cases. A higher amount of circulating tumor DNA (ctDNA) significantly correlated with clinical parameters related to tumor burden (elevated lactate dehydrogenase and beta 2-microglobulin serum levels, advanced stage, and high-risk International Prognostic Index) and total metabolic tumor volume assessed by PET/CT. In patients treated with curative intent, high ctDNA levels (>2.5 log hGE/mL) were associated with lower complete response (65% vs. 96%; P < 0.004), shorter progression-free survival (65% vs. 85%; P = 0.038), and overall survival (73% vs. 100%; P = 0.007) at 2 years, although it did not maintain prognostic value in multivariate analyses. Conclusions: In a population-based prospective DLBCL series, cfDNA resulted as an alternative source to estimate tumor burden and to determine the tumor mutational profile and genetic classification, which have prognostic implications and may contribute to a future tailored treatment.
[+]

Keywords

classificationdiagnosispet/ctsubtypesAdnAdultAgedAged, 80 and overBiomarkers, tumorCancerCèl·lules bCirculating tumor dnaClassificationDiagnosisDnaFemaleGenética médicaHigh-throughput nucleotide sequencingHumansKaplan-meier estimateLimfomesLymphoma, large b-cell, diffuseLymphomasMaleMedical geneticsMiddle agedMutationPet/ctPositron emission tomography computed tomographyPrognosisPronòstic mèdicProspective studiesSubtypesTumor burdenVolumeYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal CLINICAL CANCER RESEARCH due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2021, it was in position 17/245, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 4.56. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 3.21 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-04, the following number of citations:

  • WoS: 78
  • Scopus: 60
  • Europe PMC: 28
  • Google Scholar: 5
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 70.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 70 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 18.
  • The number of mentions on the social network X (formerly Twitter): 16 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Rivas Delgado, Alfredo ) and Last Author (López Guillermo, Armando).

the author responsible for correspondence tasks has been Rivas Delgado, Alfredo .

[+]

Awards linked to the item

This work was supported by the Instituto de Salud Carlos III, the Ministerio de Ciencia e Innovacion, and the European Regional Development Fund Una manera de hacer Europa (grants PI16/00420 and PI19/00887 to A. Lopez-Guillermo and E. Gine, and grants RTI2018-094274-B-I00 and SAF2016-81860-REDT to E. Campo); CIBERONC (grants CB16/12/00334 and CB16/12/00225); Accio instrumental de Programes de Recerca Orientats from Generalitat de Catalunya (grant SLT002/16/00374 to E. Campo and A. Lopez-Guillermo); and the European Union's Horizon 2020 research and innovation programme and the Canadian Institutes of Health Research (grant 825835 to E. Campo). A. Rivas-Delgado was supported by a Josep Font grant of Hospital Clinic de Barcelona. F. Nadeu was supported by a predoctoral fellowship of the Ministerio de Ciencia e Innovacion (grant BES-2016-076372). P. Mozas was supported by Becas de Investigacion de la Fundacion Espanola de Hematologia y Hemoterapia. J. Delgado was a recipient of a grant from the Generalitat de Catalunya (grant PERIS IPFE SLT006/17/301). E. Campo is an Academia Researcher of the Institucio Catalana de Recerca i Estudis Avancats (ICREA) of the Generalitat de Catalunya. The authors acknowledge the support of the CERCA Program from Generalitat de Catalunya. They are indebted to the Genomics core facility of the Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) for their technical help. They are grateful to V. Arellano and S. Ruiz for their support. This work was partially developed at the Centre Esther Koplowitz (CEK), Barcelona, Spain.
[+]

Related Items